Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Newsletter out

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Apr 27, 2021 8:45am

189 Views

Post# 33073086

RE:RE:RE:RE:Newsletter out

Furthermore, 2nd treatment at 6 months mark can increase CR even further or at least maintain it. IMO

enriquesuave wrote:

By including the 1st 12 undertreated patients, the numbers look less attractive, but only once we can have data on 15-20 patients who correctly treated with optimized procedure, then we will have a clear picture. So far we can say 8 patients ( 2 from PH1 and 6 from PH2) have received an optimized treatment. 4 out of 5 valuable patients are CR and 3 pending. That is 80% CR so far on valuable patients. Looking very good but need more data.IMO

enriquesuave wrote:

Yes that's the important part. Patients 13-18 or the last 6 patients have all been treated with optimized procedure. Of 13,14,& 15 2 are CR or 2 out of 3 after single treatment or 67%. Still waiting on 90 days for 16,17 & 18. We need to significantly beat the competition which is 17-24% CR efficacy at 12 months to become next Gold Standard as we already beat the competition for safety,and patient friendliness ( 2 Vs many more treatment instillations), as well as less hospital time. IMO looking good, by next report we should know on remaining patients and hopefully have more treated ( up to 7 more in Q2 or by end of June)

Oilminerdeluxe wrote: If i read it correctly, the 6 treated with the right dosage:

Although very early for a statistical analysis the primary objective at 90 days for patients receiving the optimized primary Study Treatment demonstrates a 33.3% CR rate, with 50.0% data pending and only 16.7% with no response.